Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

223
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
223
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

264
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
264
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

189
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
189
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

205
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
205
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

201
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
201
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

215
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
215

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

ERS Congress 2025: highlights from the Pulmonary Vascular Diseases Assembly.

ERJ open research·2026
Same author

Placental Growth Factor Promotes Endothelial Activation and Inflammatory Remodelling in Pulmonary Hypertension.

Cardiovascular research·2026
Same author

Is reduced right ventricular power after sotatercept beneficial?

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Venular remodeling as an integral component of CTEPH Rather Than a Distinct Pathology.

American journal of respiratory and critical care medicine·2026
Same author

Clinical, Dietary, Lifestyle and Genetic Factors Associated With Age at Onset of Esophageal Adenocarcinoma.

United European gastroenterology journal·2026
Same author

Haemodynamic responses to sotatercept and parenteral prostacyclins in pulmonary arterial hypertension patients.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026

相关实验视频

Updated: Jul 20, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.2K

肺动脉高血压是肺动脉高血压.

Athénaïs Boucly1, Christian Gerges2, Laurent Savale3

  • 1Université Paris-Saclay, Faculé de Médicine, Le Kremlin-Bicêtre, France; Service de Pneumologie et Soins Intensifs Respiratoires, AP-HP, Hôpital Bicêtre, Le Kremlin-Bicêtre, France; INSERM UMRS-999, Le Kremlin-Bicêtre, France; National Heart and Lung Institute, Imperial College London, London, UK.

Presse medicale (Paris, France : 1983)
|July 29, 2023
PubMed
概括

肺动脉高血压 (PAH) 是一种影响肺动脉的渐进性疾病. 目前的治疗针对内皮功能障碍,旨在通过风险分层组合疗法实现低风险状态.

关键词:
诊断 诊断 诊断 诊断 诊断肺高血压 肺高血压 肺高血压病理生理学 病理生理学肺动脉高血压是肺动脉高血压.肺循环的肺循环.治疗疗法 治疗疗法

更多相关视频

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.0K
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

10.8K

相关实验视频

Last Updated: Jul 20, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.2K
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

21.0K
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
07:29

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats

Published on: March 8, 2019

10.8K

科学领域:

  • 心血管医学 心血管医学
  • 肺部病理学 肺部病理学
  • 罕见疾病 罕见疾病

背景情况:

  • 肺动脉高血压 (PAH) 是一种进展性疾病,其特点是肺动脉重塑和血管狭窄.
  • 未经治疗的PAH会导致肺血管阻力增加,右心室衰竭和死亡率.
  • 准确的诊断需要全面的评估,包括右心脏导管.

研究的目的:

  • 概述目前对肺动脉高血压 (PAH) 的理解和管理.
  • 描述针对PAH关键途径的既定治疗策略.
  • 突出新兴疗法和PAH研究的未来方向.

主要方法:

  • 对PAH流行病学,病理学和病理生理学当前知识的审查.
  • 基于风险分层的既定处理算法的描述.
  • 目标途径的识别:内甲蛋白,氧化和前环素.
  • 提及新出现的治疗点,包括TGF-β和PDGF通路.

主要成果:

  • 尽管在理解和治疗方面取得了进展,但PAH仍然是一个严重的临床疾病.
  • 目前的治疗包括根据最初的疾病严重程度和风险评估量身定制的组合治疗.
  • 主要目标是实现和保持患者的低风险状态.
  • 肺移植是对最严重的病例而言的一个选择,这些病例对医学治疗没有反应.

结论:

  • 对于PAH的管理,需要采用多参数风险分层方法.
  • 针对内皮功能障碍的组合疗法是目前治疗的基石.
  • 针对新途径的新兴疗法显示了未来PAH治疗的前景.
  • 持续监测和治疗升级对于改善患者的治疗结果至关重要.